Breast Cancer | Current Treatment: Physician Insights | US | 2017
The treatment of breast cancer requires a multidisciplinary approach incorporating surgery, radiotherapy, hormonal agents, targeted therapies, and chemotherapy. Treatment decisions are influenced by disease stage, resectability, and HER2 and HR status. Targeted treatment options for the HR-positive, HER2-negative segment have expanded in the United States following the market entries of Pfizer’s Ibrance (2015) and Novartis’s Kisqali (2017). This study shines a spotlight on the current treatment dynamics for HR-positive, HER2-negative breast cancer and examines how the triple-negative breast cancer population is now managed.
Questions answered:
- What are the key drivers and obstacles determining current prescribing patterns for Ibrance in HR-positive/HER2-negative metastatic breast cancer?
- What is the uptake of recently approved Kisqali in newly diagnosed HR-positive/HER2-negative metastatic breast cancer? What is surveyed oncologists’ perception of Kisqali versus Ibrance?
- In the absence of any approved targeted therapy for triple-negative breast cancer, what is the patient share of key chemotherapeutic agents and regimens prescribed to newly diagnosed patients?
- What is the most-frequently prescribed sequence of treatment for HR-positive/HER2-negative metastatic breast cancer?
Key drugs covered:
- Kisqali
- Ibrance
- Afinitor
- Abraxane
- Faslodex
Companies mentioned:
- Pfizer
- Novartis
Related Market Assessment Reports
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
